Medtronic (MDT) announced that it has received U.S. FDA approval for the Altaviva device. The minimally invasive implantable tibial neuromodulation therapy is inserted near the ankle and designed to treat urge urinary incontinence.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT:
- Leerink says removal of C-peptide requirement would benefit pump market, Tandem
- Medtronic Announces Pricing of New Senior Notes
- Medtronic initiates global pivotal study of cardiac pacing
- Medtronic’s Strategic Growth Focus and Portfolio Optimization Drive Buy Rating
- Medtronic’s Cardiac Device Study: A Key Update for Investors